Iadademstat

DRUG7 trials

Sponsors

Fox Chase Cancer Center, Oryzon Genomics S.A., National Cancer Institute (NCI), OHSU Knight Cancer Institute, Yale University

Conditions

Accelerated Phase Myeloproliferative NeoplasmAcute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseBlast Phase Myeloproliferative NeoplasmEssential ThrombocythemiaExtensive Stage Lung Small Cell CarcinomaExtensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

RecruitingNCT05546580

Oryzon Genomics S.A.Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Start: 2022-11-14End: 2025-11-30Target: 50Updated: 2024-07-29

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

RecruitingNCT06287775

National Cancer Institute (NCI)Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Start: 2025-04-08End: 2029-07-25Target: 45Updated: 2026-04-03

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

RecruitingNCT06357182

OHSU Knight Cancer InstituteAcute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia

Start: 2024-08-22End: 2026-05-29Target: 24Updated: 2025-08-12

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

RecruitingNCT06514261

National Cancer Institute (NCI)Acute Myeloid Leukemia

Start: 2024-12-18End: 2026-09-16Target: 45Updated: 2026-04-03

Iadademstat + SBRT With Atezo in ES-SCLC

RecruitingNCT07113691

Yale UniversityExtensive Stage Small Cell Lung Cancer (ES-SCLC)

Start: 2026-01-20End: 2030-01-01Target: 15Updated: 2026-03-27

Phase 2

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

TerminatedNCT05420636

Fox Chase Cancer CenterNeuroendocrine Carcinoma, Small-cell Lung Cancer

Start: 2022-12-21End: 2025-07-23Updated: 2025-07-30

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

RecruitingNCT06661915

National Cancer Institute (NCI)Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia +5

Start: 2025-08-14End: 2027-12-31Target: 62Updated: 2026-04-03

Related Papers

Targeting chemoresistance: A phase II study of iadademstat (Iada) with paclitaxel (P) in extrapulmonary neuroendocrine carcinoma (epNEC) and small cell lung cancer (SCLC).

Journal of Clinical Oncology2026-01-10

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Blood2025-11-03

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Blood2025-11-03

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Blood2025-11-03

Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study

Blood2023-11-022 citations

Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.

Journal of Clinical Oncology2023-06-01